Skip to main content
Explore URMC

menu

Multiple Cancers: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Research Question:
What are the good and bad effects of the combination of study drugs called ipilimumab and nivolumab in treating rare cancers and cancers of unknown primary origin?

Basic Study Information

Purpose:
If you participate in this study you will receive the study drugs ipilimumab and nivolumab. You will receive both study drugs through a vein on the first day of each cycle (or every 6 weeks), and you will receive nivolumab through a vein every 2 weeks. You will continue to receive study drugs until your disease gets worse or you experience bad side effects from the study drugs or your study doctor decides that you are not benefiting from the study drugs.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02834013?term=S1609&rank=1
Study Reference #: CMLT18023

Lead Researcher (Principal Investigator)

Lead Researcher: Paul Barr

Study Contact Information

Study Coordinator: Laura Mitchell
Phone: (585) 275-7763
Email: Laura_Mitchell@URMC.Rochester.edu

Additional Study Details

Return to Search